Evenity (Romosozumab) vs Tymlos (Abaloparatide): Side-Effect Profile Head-to-Head

What Are Evenity and Tymlos, and How Do They Differ?

Both Evenity and Tymlos build new bone rather than simply slowing bone loss, which puts them in a different category from bisphosphonates like alendronate or denosumab. That shared mechanism is where the similarity mostly ends. The drugs hit different molecular targets, require different injection schedules, carry different boxed warnings, and suit different clinical profiles.

Romosozumab (Evenity) works by inhibiting sclerostin, a protein that normally suppresses bone formation. Block sclerostin and you simultaneously increase bone formation and decrease bone resorption. This dual action is unique among approved osteoporosis drugs. The treatment window is exactly 12 monthly injections given in a clinical setting, after which you must transition to an antiresorptive.

Abaloparatide (Tymlos) is a synthetic analog of parathyroid hormone-related protein (PTHrP). It binds preferentially to the RG conformation of the PTH1 receptor, which is thought to favor bone formation over resorption more selectively than teriparatide does. You self-inject Tymlos daily for up to 24 months, and like Evenity, you follow it with an antiresorptive.

Why "anabolic first" matters for women

Bone density peaks in your late 20s and begins a slow decline from there. The steepest losses happen in the two to three years immediately after your final menstrual period, when estrogen withdrawal accelerates osteoclast activity sharply. Antiresorptives can slow that loss but cannot rebuild the architectural strength already gone. Anabolic agents can. For women who arrive at their 60s or 70s with a vertebral compression fracture already on imaging, starting with a bone-builder rather than a bone-preserver is the approach now favored by The Menopause Society 2023 position statement on osteoporosis management.

The sclerostin pathway and estrogen

Estrogen normally suppresses sclerostin in bone. After menopause, sclerostin levels rise as estrogen falls, which partly explains accelerated bone loss. Romosozumab targets this exact mechanism. This is not a coincidence: the drug was specifically developed with postmenopausal physiology in mind. There are no meaningful efficacy data for romosozumab in premenopausal women, and the approved indication reflects that.

Head-to-Head Side-Effect Comparison

There is no published randomized trial comparing romosozumab directly against abaloparatide. What follows synthesizes the key trial data for each drug separately. Treat cross-trial comparisons with appropriate caution because populations, comparators, and follow-up periods differ.

Cardiovascular risk: Evenity's boxed warning

The ARCH trial (NEJM, 2017) randomized 4,093 postmenopausal women with osteoporosis to romosozumab 210 mg monthly or alendronate 70 mg weekly for 12 months, then both groups transitioned to alendronate. The romosozumab arm showed a 48% reduction in new vertebral fractures compared with alendronate alone. Impressive efficacy. The concern: serious cardiovascular events, including myocardial infarction and stroke, were numerically higher in the romosozumab group during the 12-month treatment phase. The absolute difference was small (2.5% vs 1.9%), but the FDA took it seriously enough to require a boxed cardiovascular warning.

What this means for you: Evenity is contraindicated if you have had a heart attack or stroke within the past year. If you have established cardiovascular disease or multiple cardiac risk factors, you and your clinician need to weigh whether the fracture-risk reduction justifies the cardiovascular signal before starting Evenity.

The earlier FRAME trial (NEJM 2016) of romosozumab vs placebo did not show the same cardiovascular imbalance, which suggests the signal in ARCH may partly reflect a protective effect of alendronate in the comparator arm rather than pure toxicity from romosozumab. The honest answer is that the mechanism is not fully resolved.

Osteosarcoma risk: Tymlos's boxed warning

The ACTIVE trial (JAMA, 2016) randomized 2,463 postmenopausal women to abaloparatide 80 mcg daily, teriparatide 20 mcg daily, or placebo for 18 months. Abaloparatide reduced new vertebral fractures by 86% vs placebo and cut nonvertebral fractures by 43%.

Tymlos carries a boxed warning for osteosarcoma, which is based on dose-dependent tumor development in rats given the drug at exposures far exceeding human clinical doses over most of a rat's lifetime. No causal link to osteosarcoma has been established in humans. The FDA caps cumulative lifetime use of abaloparatide (and the related drug teriparatide) at 2 years total across a patient's lifetime, citing this theoretical concern. For practical purposes, most physicians treating postmenopausal women view the osteosarcoma risk as a theoretical precaution rather than a clinically documented hazard in adults.

Injection-site reactions

Both drugs are subcutaneous injections. Injection-site reactions, meaning redness, pain, swelling, and bruising, are common with both.

In ACTIVE, injection-site reactions occurred in roughly 58% of abaloparatide users vs 20% of placebo patients. Most were mild. In the ARCH trial, injection-site reactions with romosozumab were reported in around 17% of participants.

Tymlos is a daily injection you give yourself at home. Evenity is a monthly injection administered in a clinical office or by a healthcare professional. The daily injection burden of Tymlos is real, and adherence data consistently show that daily injectable regimens have lower long-term persistence than monthly regimens.

Hypercalcemia and hypercalciuria

Because abaloparatide activates PTH1 receptors, transient elevations in serum calcium can occur, though less frequently than with teriparatide. In ACTIVE, hypercalcemia occurred in 3.4% of abaloparatide patients vs 6.4% with teriparatide. Romosozumab does not meaningfully raise serum calcium because its mechanism does not directly stimulate PTH signaling.

If you have a history of kidney stones, hypercalciuria, or primary hyperparathyroidism, Evenity is the safer choice from a calcium-handling perspective.

Orthostatic hypotension

Abaloparatide can cause orthostatic hypotension, dizziness, and palpitations, particularly in the first several months of use. ACTIVE protocol required patients to sit or lie down for 30 minutes after the first injection. If you have a history of syncope, poorly controlled hypertension, or take antihypertensives that already lower standing blood pressure, discuss this with your clinician before starting Tymlos.

Romosozumab does not carry this orthostatic concern.

Hypersensitivity and antibody formation

Both drugs can provoke injection-site hypersensitivity. Romosozumab antibody formation was reported in approximately 18% of ARCH patients, though neutralizing antibodies that actually blunt efficacy were rare. Abaloparatide antibody rates were low in ACTIVE and did not appear to affect efficacy.

Side effects at a glance

| Side effect | Romosozumab (Evenity) | Abaloparatide (Tymlos) | |---|---|---| | Cardiovascular (MI, stroke) | Boxed warning; 2.5% in ARCH | No signal in ACTIVE | | Osteosarcoma | No warning | Boxed warning (rat data) | | Injection-site reactions | ~17% | ~58% | | Hypercalcemia | Rare | 3.4% | | Orthostatic hypotension | No | Yes (first doses) | | Nausea | Uncommon | Mild, transient | | Antibody formation | ~18% (rarely neutralizing) | Low | | Headache | Reported | Reported | | Arthralgia | Common | Less common |

Fracture Efficacy: What the Trials Actually Show

Fracture prevention is the reason these drugs exist, so efficacy matters as much as tolerability.

Romosozumab in ARCH

The ARCH trial is the key romosozumab-vs-active-comparator study. After 24 months of total follow-up (12 months romosozumab, then both groups on alendronate), romosozumab-then-alendronate reduced new vertebral fractures by 48% and clinical fractures by 27% compared with alendronate alone from the start. This "anabolic first, antiresorptive second" sequence produced greater gains than going straight to alendronate. Hip fracture reduction reached statistical significance: a 38% relative risk reduction.

Abaloparatide in ACTIVE

The ACTIVE trial over 18 months showed an 86% relative reduction in new vertebral fractures for abaloparatide vs placebo and a 43% reduction in nonvertebral fractures. The ACTIVExtend extension, where both groups transitioned to alendronate after abaloparatide or placebo, maintained and extended those gains.

Honest cross-trial caveat

You cannot directly rank these drugs by their trial efficacy numbers because the trials used different comparators (alendronate vs placebo), different durations, and different populations. The 86% vertebral fracture reduction for abaloparatide was against placebo; the 48% for romosozumab was against an active drug. The placebo comparison is always going to look more dramatic.

Who This Is Right For, and Who Should Choose the Other

Evenity may be a better fit if you:

• Are postmenopausal with very high fracture risk and have not had a heart attack or stroke in the past year
• Prefer monthly clinic visits over daily self-injection
• Have a history of calcium-related kidney stones (romosozumab does not raise calcium)
• Have already tried an antiresorptive and continue to fracture (anabolic escalation)

Tymlos may be a better fit if you:

• Are postmenopausal with high fracture risk and have established cardiovascular disease or recent cardiac events
• Can manage a daily self-injection routine
• Need up to 24 months of anabolic therapy rather than 12
• Have not used any PTH-pathway anabolic agent before (2-year lifetime cap applies to the class)

Neither drug is appropriate if you:

• Have had prior radiation therapy involving the skeleton (increased osteosarcoma concern with Tymlos)
• Have Paget disease of bone, unexplained alkaline phosphatase elevation, or bone metastases (both drugs)
• Are pregnant or may become pregnant (see next section)
• Are premenopausal (no efficacy data; not an approved indication for either agent in standard practice)

Pregnancy, Lactation, and Contraception

Both romosozumab and abaloparatide are contraindicated in pregnancy. Neither drug is approved for use during lactation.

This section is mandatory for any drug article on WomanRx, and it requires plainness: if you are pregnant, trying to conceive, or not using reliable contraception, do not start either drug.

Romosozumab in pregnancy

Romosozumab has no controlled human pregnancy data. Animal studies showed fetal harm at exposures exceeding clinical doses. The FDA classifies it as a drug to avoid in pregnancy. Because the approved indication is postmenopausal osteoporosis, most prescribers will not encounter this scenario. A rare exception is a premenopausal woman with glucocorticoid-induced osteoporosis or a genetic bone-fragility syndrome, in which case pregnancy prevention during treatment and for a wash-out period afterward must be addressed explicitly. The FDA prescribing information does not define a specific wash-out duration given the monthly injection interval and the serum half-life of approximately 6 days.

Abaloparatide in pregnancy

Abaloparatide similarly has no adequate human pregnancy data. Animal reproductive studies showed adverse developmental effects. The osteosarcoma signal in rats adds a theoretical dimension of concern, though extrapolation to human fetal risk is speculative. FDA labeling contraindicates use in pregnancy. The drug's half-life is approximately 1 hour, so clearance after stopping is rapid, but the downstream skeletal effects of PTH1 receptor activation during fetal bone development are not studied in humans.

Lactation

Neither drug has human lactation data. Given the large molecular size of romosozumab and the very short half-life of abaloparatide, clinicians sometimes speculate that transfer into breast milk may be limited. Speculation is not data. Neither drug should be used during breastfeeding.

Premenopausal women with osteoporosis

Severe osteoporosis in a woman of reproductive age is uncommon but real. It occurs in the context of anorexia nervosa, glucocorticoid therapy, aromatase inhibitor use, or premature ovarian insufficiency. If you are premenopausal and being considered for anabolic therapy, you need a clinician experienced in premenopausal bone disease, a detailed conversation about contraception, and a plan that accounts for the possibility of pregnancy. The evidence base for either drug in premenopausal women is thin. Teriparatide has more premenopausal use data than either romosozumab or abaloparatide, though none of these drugs have strong randomized trial data in women under 45.

Life Stage Breakdown: When Does Bone-Building Therapy Enter the Picture?

Reproductive years (20s to early 40s)

Peak bone mass forms by your late 20s. Lifestyle factors, specifically calcium intake, vitamin D, weight-bearing exercise, and avoiding smoking, matter most here. Neither Evenity nor Tymlos is standard of care at this stage. Bone density testing is not routine unless you have specific risk factors.

Perimenopause (typically 40s to early 50s)

Bone loss accelerates in the 2 to 3 years before your final period. The Menopause Society recommends DEXA scanning for women entering menopause with risk factors (prior fracture, family history, low body weight, glucocorticoid use, smoking). Anabolic therapy is not typically the starting point at this stage. Menopausal hormone therapy (MHT), if otherwise appropriate, reduces bone loss and may defer the need for osteoporosis medication.

Early postmenopause (50s)

If your T-score is between -1.0 and -2.5 (osteopenia) and FRAX 10-year hip fracture probability is <3%, lifestyle measures and possibly MHT are appropriate first steps. If T-score is <-2.5 or you have a prior low-trauma fracture, AACE guidelines support pharmacotherapy, starting with antiresorptives for most women and reserving anabolics for those at very high or imminent fracture risk.

Late postmenopause (60s and beyond)

This is where Evenity and Tymlos most commonly enter the picture. A woman in her late 60s with a T-score of -3.0 and a prior vertebral fracture has imminent fracture risk and stands to gain substantially from anabolic therapy, followed by an antiresorptive to consolidate gains.

Sequential Therapy: What Comes After Evenity or Tymlos?

Both drugs must be followed by an antiresorptive. Without a subsequent antiresorptive, the bone density gains reverse within 12 months of stopping either drug.

The following sequential framework is used by bone specialists at WomanRx when advising postmenopausal patients with high fracture risk:

Step 1. Confirm very high or imminent fracture risk (prior fracture, T-score <-2.5 on therapy, or FRAX 10-year major osteoporotic fracture risk above 20%).

Step 2. Address cardiovascular history. If recent MI or stroke: choose abaloparatide or teriparatide. If history of nephrolithiasis or hypercalciuria: choose romosozumab.

Step 3. Choose the anabolic phase:

• Romosozumab 210 mg monthly x 12 months (clinic-administered), OR
• Abaloparatide 80 mcg daily x up to 24 months (self-administered)

Step 4. Transition without gap to an antiresorptive: denosumab 60 mg every 6 months provides the strongest bone density consolidation after romosozumab per the FRAME-E extension data. Alendronate 70 mg weekly is an evidence-backed option after abaloparatide per ACTIVExtend.

Step 5. Monitor with DEXA at 12 to 24 months and bone turnover markers (CTX, P1NP) to confirm the antiresorptive is working.

This is a framework for discussion with your clinician, not a substitute for individualized assessment.

Can You Switch Between Evenity and Tymlos?

Switching from Evenity to Tymlos, or the reverse, is not a common clinical scenario. But it comes up. Here is what the available evidence says.

If you complete 12 months of romosozumab and cannot tolerate or access the subsequent antiresorptive, a clinician might consider abaloparatide as a bridge, though this sequence is not backed by dedicated trial data. The lifetime 2-year cap on PTH-pathway agents (abaloparatide plus teriparatide combined) would need to be accounted for.

Going the other direction, from abaloparatide to romosozumab, is even less studied. Romosozumab's sclerostin-inhibition mechanism is distinct from PTH1 receptor signaling, so there is no pharmacological reason the drugs would interfere with each other. The practical barrier is that romosozumab is approved for 12 months only, and if you have already used it, you cannot repeat it. Tymlos carries the 2-year class cap. Once both are exhausted, antiresorptives become the long-term maintenance strategy.

Monitoring, Vitamin D, and Calcium Co-requirements

Both drugs require adequate calcium and vitamin D status before and during treatment.

The National Osteoporosis Foundation recommends 1,200 mg elemental calcium daily (from food plus supplements) for women over 50, and vitamin D intake of 800 to 1,000 IU daily. Serum 25-hydroxyvitamin D should be above 30 ng/mL before starting either drug.

For Tymlos specifically, calcium supplementation can blunt the transient hypercalcemia after injection, but because abaloparatide raises calcium less than teriparatide, ACTIVE investigators did not require calcium timing restrictions relative to injection time. For Evenity, calcium monitoring is not driven by hypercalcemia risk but rather because the drug can transiently lower calcium in vitamin D-deficient patients; correct deficiency before starting.

Lab monitoring recommended during anabolic therapy:

• Serum calcium and 25-hydroxyvitamin D at baseline and 3 months
• Renal function (eGFR) at baseline
• P1NP (bone formation marker) at baseline and 3 to 6 months to confirm anabolic response
• CTX (bone resorption marker) at baseline

A Note on the Evidence Gap in Women

Both ARCH and ACTIVE enrolled almost exclusively postmenopausal women, which is appropriate given the indication. This means the evidence base for these drugs in women is stronger than for many areas of women's health. That is worth naming. However:

• Subgroup analyses by age, race, and baseline T-score are limited in both trials.
• Women over 80 with frailty were underrepresented.
• Black and Hispanic women, who have different baseline fracture risk profiles and different rates of vitamin D deficiency, were enrolled in small numbers in both trials.

The honest clinical implication is that the absolute fracture risk reduction numbers from ARCH and ACTIVE apply most cleanly to white postmenopausal women aged 55 to 75. Extrapolation beyond that range is reasonable but not directly supported by the trial data.